small molecule drugs

A unique collection of xnum FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of xnum approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);

xnum Chemotherapeutic drugs that can be used for high-throughput and high-content screening.

A unique collection of xnum GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of xnum anticancer drugs for high throughput screening (HTS) and high content screening (HCS);

A collection of xnum selected human endogenous metabolites for high throughput and high content screening.

A unique collection of xnum promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of xnum rare natural products, which can be used for high throughput screening (HTS) and high content screening (HCS);

The library consists of 3745 members belonging 22 scaffolds (average 180 compounds per scaffold).

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981. Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function. The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

A unique collection of xnum EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

xnum tumor-targeted drugs that can be used for high-throughput and high-content screening.

A unique collection of xnum compounds targeting histaminergic receptor and melatonin receptor for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of xnum anti-inflammation compounds effective for high throughput screening and high content screening.

xnum non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.

A unique collection of xnum pure natural products with diverse structures and sources covering various plant, animal, and microbe species;

xnum drug fragments,a must-have tool for FBDD;

A unique collection of xnum compounds for high-throughput screening and high-content screening,

A unique collection of xnum covalent Inhibitors and other molecules with common warheads like chloroacetyl,2-Chloropropionyl,Acryloyl,sulfonyl fluoride, alkyne,acrylamide, ketocarbonyl,disulfide bond, etc.

A unique collection of xnum types of multi-target compounds for high throughput screening (HTS) and high content screening (HCS);